| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2023 ( Subtotal = $2,127,405 ) (Continued on the next page) |
| | 2023 | 2023 | MAYO CLINIC | 200 FIRST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R21CA267098 | Targeting poly (ADP ribose) polymerase (PARP) in endometrial cancer | 000 | 2 | NIH | 11/23/2022 | $167,249 |
| | 2023 | 2023 | MAYO CLINIC | 200 FIRST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01CA237398 | Role of Nuclear Pore-Regulated Mechanisms in Prostate Cancer Aggressiveness | 000 | 5 | NIH | 11/2/2022 | $353,458 |
| | 2023 | 2023 | MAYO CLINIC | 200 FIRST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | K01AA028050 | Acamprosate pharmacogenomics: iPSC based model of alcohol use disorder | 000 | 4 | NIH | 11/22/2022 | $129,750 |
| | 2023 | 2023 | MAYO CLINIC | 200 FIRST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01NS076491 | Computational and Biological Approach to Flow Diversion | 000 | 12 | NIH | 11/16/2022 | $562,569 |
| | 2023 | 2023 | MAYO CLINIC | 200 FIRST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R37CA266344 | Towards Safer and More Effective CART Cell Therapy Through the Modulation of Myeloid Cytokines | 000 | 2 | NIH | 11/22/2022 | $568,868 |
| | 2023 | 2023 | MAYO CLINIC | 200 FIRST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | K23AI143882 | Beta-lactam individualization for critically ill patients | 000 | 4 | NIH | 11/3/2022 | $197,640 |
| | 2023 | 2023 | MAYO CLINIC | 200 FIRST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01CA235026 | Integration of germline and tumor genomes in CLL | 000 | 5 | NIH | 11/16/2022 | $571,429 |
| | 2023 | 2023 | MAYO CLINIC | 200 FIRST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01HL160761 | Mechanisms of Clinical and Hemodynamic Response to Pulmonary Vasodilator Therapy in Fontan physiology | 000 | 2 | NIH | 11/23/2022 | $575,982 |
| | 2023 | 2023 | MAYO CLINIC | 200 FIRST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R35HL139854 | Variant Hemoglobin and Cardiorespiratory Regulation in Humans | 001 | 6 | NIH | 11/16/2022 | $725,565 |
| | 2023 | 2023 | MAYO CLINIC | 200 FIRST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | U01HL152967 | Therapeutic ECM Resorption in Cellular Systems and Precision Cut Lung Slices. | 000 | 3 | NIH | 11/23/2022 | $633,152 |
| | 2023 | 2023 | MAYO CLINIC | 200 FIRST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01CA256927 | Targeting dual functions of PD-L1 for cancer therapy | 000 | 3 | NIH | 11/10/2022 | $327,341 |
| | 2023 | 2022 | MAYO CLINIC | 200 FIRST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01HS028639 | SDMo ? a measure of the occurrence of SDM in the care of patients with chronic conditions | 000 | 1 | AHRQ | 10/20/2022 | $0 |
| | 2023 | 2022 | MAYO CLINIC | 200 FIRST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | P20DK135097 | Renal macrophages in the pathogenesis of human urinary stones and Randall's plaque formation in mice | 000 | 1 | NIH | 10/18/2022 | $0 |
| | 2023 | 2022 | MAYO CLINIC | 200 FIRST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | K23MD017217 | Working to Eliminate Care Disparities in Liver Cancer in Southeast Asian Americans: Transportation and Other Social Determinants of Health. | 001 | 1 | NIH | 10/24/2022 | $0 |
| | 2023 | 2022 | MAYO CLINIC | 200 FIRST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | U01CA195568 | The Lymphoma Epidemiology of Outcomes (LEO) Cohort Study (Supplement) | 000 | 7 | NIH | 11/17/2022 | $0 |
| | 2023 | 2022 | MAYO CLINIC | 200 FIRST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | K23MD017217 | Working to Eliminate Care Disparities in Liver Cancer in Southeast Asian Americans: Transportation and Other Social Determinants of Health. | 000 | 1 | NIH | 10/20/2022 | $0 |
| | 2023 | 2022 | MAYO CLINIC | 200 FIRST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R33AG069767 | Definition and Caregiver Appraisal of Paradoxical Lucidity in Dementia | 000 | 3 | NIH | 11/2/2022 | $0 |
| | 2023 | 2022 | MAYO CLINIC | 200 First St SW | Rochester | MN | 55905-0001 | OLMSTED | USA | U01DP006703 | Epidemiology of Lupus: Longitudinal Studies in Population-Based Cohorts - 2022 | 01 | 1 | CDC | 10/20/2022 | $0 |
| | 2023 | 2022 | MAYO CLINIC | 200 FIRST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | U01CA271014 | Impact of Genetic susceptibility along the continuum from MGUS to MM (Supplement) | 000 | 1 | NIH | 11/21/2022 | $0 |
| | 2023 | 2022 | MAYO CLINIC | 200 FIRST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | P01AG062413 | Targeting Cellular Senescence to Extend Healthspan | 000 | 4 | NIH | 10/27/2022 | $0 |
| | 2023 | 2022 | MAYO CLINIC | 200 FIRST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | UH3NS113776 | Small Molecule Mitochondria-Targeted Therapeutics for AD | 000 | 2 | NIH | 11/15/2022 | $0 |
| | 2023 | 2022 | MAYO CLINIC | 200 FIRST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R03EB032958 | Development of non-contact rheometry for measuring rheological properties of biological fluids | 000 | 1 | NIH | 11/15/2022 | -$73,324 |
| | 2023 | 2022 | MAYO CLINIC | 200 FIRST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | K12CA090628 | Paul Calabresi Program in Clinical/Translational Research at Mayo Clinic | 000 | 22 | NIH | 11/1/2022 | $0 |
| | 2023 | 2022 | MAYO CLINIC | 200 FIRST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01CA259201 | Hereditary Genetics of Hepatocellular Carcinoma | 000 | 2 | NIH | 10/24/2022 | $0 |
| | 2023 | 2022 | MAYO CLINIC | 200 FIRST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01DK129315 | Neurobiology of Intrinsic Primary Afferent Neurons | 000 | 2 | NIH | 11/24/2022 | $0 |
| | 2023 | 2022 | MAYO CLINIC | 200 FIRST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01AR077518 | Immune Checkpoint Inhibition and humoral immune response in systemic autoimmunity | 000 | 2 | NIH | 10/21/2022 | $0 |
| | 2023 | 2022 | MAYO CLINIC | 200 FIRST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R35HL139854 | Variant Hemoglobin and Cardiorespiratory Regulation in Humans | 000 | 5 | NIH | 11/3/2022 | $0 |
| | 2023 | 2022 | MAYO CLINIC | 200 FIRST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | KL2TR002379 | Institutional Career Development Core | 000 | 6 | NIH | 10/24/2022 | $0 |
| | 2023 | 2021 | MAYO CLINIC | 200 FIRST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01AR071338 | 4D CT Imaging for Improved Diagnosis and Treatment of Wrist Ligament Injuries | 000 | 5 | NIH | 11/16/2022 | -$43,181 |
| | 2023 | 2021 | MAYO CLINIC | 200 FIRST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R03DK122187 | Innate Immune Response Following Bacterial Translocation in Early Life | 000 | 2 | NIH | 10/14/2022 | $0 |
| | 2023 | 2021 | MAYO CLINIC | 200 FIRST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01AI147394 | Balancing protective immunity and chronic sequelae by resident CD8 T cells | 002 | 2 | NIH | 11/10/2022 | $0 |
| | 2023 | 2021 | MAYO CLINIC | 200 FIRST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01AI147394 | Balancing protective immunity and chronic sequelae by resident CD8 T cells | 000 | 2 | NIH | 10/13/2022 | -$345,685 |
| | 2023 | 2021 | MAYO CLINIC | 200 FIRST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01AI112844 | Molecular regulation of protective CD8 immunity against influenza infection | 000 | 8 | NIH | 10/13/2022 | -$25,486 |
| | 2023 | 2021 | MAYO CLINIC | 200 FIRST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | UH3DA042492 | Definitive Preclinical Studies of Hydrolase Gene Transfer to Treat Cocaine Abuse | 000 | 5 | NIH | 10/17/2022 | $0 |
| | 2023 | 2021 | MAYO CLINIC | 200 FIRST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01HL146461 | Epithelial stem cell hippo signaling in pulmonary fibrosis | 000 | 4 | NIH | 11/1/2022 | $0 |
| | 2023 | 2021 | MAYO CLINIC | 200 FIRST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01GM128579 | Cell-Penetrating Aptamers Targeting Sub-Cellular Compartments | 000 | 4 | NIH | 11/15/2022 | $0 |
| | 2023 | 2021 | MAYO CLINIC | 200 FIRST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01NS107265 | Small molecule mitochondria-targeted therapeutics for Huntingtons Disease | 000 | 4 | NIH | 10/19/2022 | -$10,170 |
| | 2023 | 2021 | MAYO CLINIC | 200 FIRST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | K76AG057015 | Cerebral Microbleeds in the Aging Population | 000 | 5 | NIH | 10/28/2022 | -$8,048 |
| | 2023 | 2021 | MAYO CLINIC | 200 First St SW | Rochester | MN | 55905-0001 | OLMSTED | USA | 90DPTB0012 | Mayo Clinic Traumatic Brain Injury Model System | 01 | 5 | ACL | 10/12/2022 | $0 |
| | 2023 | 2021 | MAYO CLINIC | 200 FIRST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01CA261925 | Determine the Microphthalmia Transcription Factor (MITF)-regulated cell rewiring mechanisms in lethal prostate cancer | 001 | 2 | NIH | 10/12/2022 | $15,739 |
| | 2023 | 2021 | MAYO CLINIC | 200 FIRST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | UG3NS113776 | Small molecule mitochondria-targeted therapeutics for AD | 000 | 1 | NIH | 11/9/2022 | $0 |
| | 2023 | 2021 | MAYO CLINIC | 200 FIRST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01HL134664 | ENHANCING CARDIOPOIETIC REGENERATION FOR ISCHEMIC CARDIOMYOPATHY | 000 | 4 | NIH | 11/14/2022 | $0 |
| | 2023 | 2021 | MAYO CLINIC | 200 FIRST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | U01EB024450 | High-performance compact 3T MRI: Technical optimization for advanced brain imaging | 000 | 5 | NIH | 11/8/2022 | $0 |
| | 2023 | 2021 | MAYO CLINIC | 200 FIRST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01CA233522 | Role of RBBP4/p300 Complex in Recovery from therapy induced DNA damage in glioblastoma | 002 | 2 | NIH | 11/18/2022 | $2,134 |
| | 2023 | 2021 | MAYO CLINIC | 200 FIRST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01CA233522 | Role of RBBP4/p300 Complex in Recovery from therapy induced DNA damage in glioblastoma | 000 | 2 | NIH | 10/19/2022 | -$2,134 |
| | 2023 | 2021 | MAYO CLINIC | 200 FIRST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01CA213645 | Effectiveness of screening for colorectal cancer in average risk adults: Colonoscopy vs FIT | 000 | 6 | NIH | 11/22/2022 | -$97,041 |
| | 2023 | 2021 | MAYO CLINIC | 200 FIRST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R21AI146804 | Th2A cells mediate outcomes of aspirin exacerbated respiratory disease | 000 | 3 | NIH | 11/2/2022 | $0 |
| | 2023 | 2021 | MAYO CLINIC | 200 FIRST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01AR071338 | 4D CT Imaging for Improved Diagnosis and Treatment of Wrist Ligament Injuries | 001 | 5 | NIH | 11/16/2022 | -$9,926 |
| | 2023 | 2020 | MAYO CLINIC | 200 FIRST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01HL132854 | Cardiorenal Fibrosis: Biology and Therapeutics | 000 | 5 | NIH | 11/10/2022 | $0 |
|
